Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GV1001 Vaccination in Locally Advanced NSCLC
NCT00509457Phase 2Completed
- Sponsor
- Oslo University Hospital
- Start
- Nov 2006
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tertomotide in non-small cell lung cancer (NSCLC), sponsored by Oslo University Hospital. Primary endpoint: Immunological Response. Started Nov 2006; status: completed.
02
Drugs
tertomotide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00509457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00509457.